Fuji Health Science Introduces New Dietary Ingredient Notification (NDIN) for AstaREAL
"With this successful NDIN, Fuji reaffirms once again its commitment to quality and safety as its number one priority," said Charles DePrince, president of Fuji Health Science. "Also, as earlier testament to this, AstaReal still remains the only astaxanthin that has successfully petitioned a notification to the FDA for GRAS status also receiving a no-objection letter back in January 2010 for that as well.”
Feb 27 2012 --- Fuji Health Science, Inc. reported a successful new dietary ingredient notification (NDIN) for its AstaREAL astaxanthin (12 g/d) after receiving a letter of no objection from FDA. According to the company, the purpose of the new NDIN was to support the dietary supplement industry’s widening range of potential astaxanthin users.
"With this successful NDIN, Fuji reaffirms once again its commitment to quality and safety as its number one priority," said Charles DePrince, president of Fuji Health Science. "Also, as earlier testament to this, AstaREAL still remains the only astaxanthin that has successfully petitioned a notification to the FDA for GRAS status also receiving a no-objection letter back in January 2010 for that as well.”
Joe Kuncewitch, Fuji's national sales manager said the astaxanthin market is finally reaching maturity. "Up until this past year it was a specialty ingredient carried only by select customers but astaxanthin has now gone mainstream, finding itself in Mass Market," explained. " The spark that ignited the astaxanthin explosion was Dr. Oz, introducing astaxanthin on his TV show last year. A year later we continue to see market expansion."
All content and features on this website are copyrighted with all rights reserved. The full details can be found in our privacy statement
